severe hypertension (4) initiation of obstetrical management. The use of anticonvulsant treatment varies in different parts of the world. A large multi center study has shown that Magnesium Sulphate is the ideal anticonvulsant 2 .
In Bangladesh no institution has more experience than Dhaka Medical College Hospital (DMCH), where 500 to 800 eclamptic patients are admitted every year. In DMCH MgSO 4 has been used as a routine anticonvulsant from the beginning of 1998 after the commencement of its regular supply from the central medical store. We follow the dose schedule according to the guidelines published by Eclampsia Working Group 3 . The dose schedule is 4 gm intravenous (IV),given in diluted form and 3 gm intramuscular (IM) in each buttock -a total of 10 gm as a loading dose, followed by 2.5 gm IM every 4 hr in alternate buttock until 24 hrs after delivery or the last fit. This is almost half of dose described by the standard Pritchard regimen 4 in which 5 gm of MgSO 4 is administered four hourly for 24 hours after loading with 14 grams; as patient would require at least 44 grams of the drug to complete a course. As weight of the average Bangladeshi women is light, this small dose appears to control convulsions effectively as established in different trials 5 and is recommended by Eclampsia Working Group 3 .
MgSO 4 that we are using in DMCH is an important preparation supplied by CMSD (Central medical store), the supply of which is inadequate many a time. On the other hand, Nalepsin (100 ml of 4% Mg Heptahydrate) marketed by a local pharmaceutical company is available all over the country.
The dose schedule for loading dose of MgSo 4 that we are currently using has both IV and IM component. Preparing the IV and IM component is cumbersome. For a loading dose total 4 ampules of drug are required, which is to be divided for IV and IM portion. Health care providers are to be trained for preparing the total schedule. So preparation needs both time and expertise. Moreover, IM component contains 3 gm (6 ml ) MgSo 4 and this voluminous drug by IM route is very painful, sometimes it may cause abscess formation.
On the other hand schedule of IV inj Nalepsin is different. It includes 4 gm (100 ml) IV running at 60 drops/ m then 2 gm (50 ml) at 12 drops/minute and finally it is to be continued @ 6 drops/minute for 24 hrs.Though it is safe, giving continuous IV drip might bear risk if someone increases the drip inadvertently. We intended to modify the existing loading dose of IV/IM regim to avoid dilution of the drug and intramuscular component of loading dose. In our study we used 2 bag of inj Nalepsin ie total 8 gm of drug IV stat at loading dose. It is much easier to administer only by IV route and less training of health care provider is needed. Moreover, with only IV dose schedule painful IM injection could be avoided.
So purpose of this study was to explore the efficacy of 8 gm mgso4 as loading dose instead of 10 gm to control and prevent recurrence of convulsion in eclampsia.
Materials and methods :
During the period of April to October 2010,from all patients admitted in Eclampsia Unit of DMCH , a total 100 patients (50 MgSO 4 group and 50 Nalepsin group) were purposively selected.Only antepartum and intrapartum cases were included. Exclusion criteria were, patients with severe morbidity like CVA, HELLP Syndrome, DIC, renal failure, pulmonary oedema and patients having contraindication for using MgSO 4. Fifty patients were managed by 10 gm MgSO 4 loading dose (group A). Dose schedule for group A: 4 gm (8 ml) of MgSO 4 dissolved in 12 ml of distilled water given IV and slowly over 20 minutes followed by 3 gm (6 ml) MgSO 4 deep IM in each buttock.
Another 50 patients were managed by 8 gm of Nalepsin (Group B).Dose schedule for group B: Injection Nalepsin 4 gm (100 ml of 4% magnesium heptahydrate) IV at a rate of 60 drops per minute over 25 minutes, followed by inj. Nalepsin 4 gm (100 ml) in IV infusion at the rate of 45 drops per minute over 30 mins. So it took 35 minutes more to complete the loading dose. In both groups maintenance dose was given by the same protocol in eclampsia unit of Dhaka Medical College Hospital ie 2.5 gm MgSo 4 IM in alternate buttock 4 hourly for 24 hours.
Beside the anticonvulsant, patients of both groups were managed by the same protocol for eclampsia management recommended by the Eclampsia Working Group of Bangladesh.
Student t test and Chi-square test were done as appropriate for test of significance and a p value of <0.05 is considered significant.
Result :
Rate of maternal complication at admission was higher in group A, leaded by pulmonary oedema and Table I shows the patients' characteristics, which was similar in both the groups. Baseline parameters of all patients were almost similar and there was no difference between two groups (Table II) . Number of convulsion, time interval between 1 st convulsion and admission, starting of treatment and delivery was same in both the groups (Table III) . The different dose schedule did not effect in mode of delivery, which was similar in both the groups. Normal vaginal delivery and caesarean section is almost equal in both groups and rate of instrumental delivery is very low (Table IV) . Chi-square test was done for categorical data and t test was done for quantitative data to measure the level of significance. ns = Not significant, * = Significant.
Foetal outcome was also similar in both groups in terms of live birth rate 88% vs 84% , good apgar score 72.7% vs 59.5% and mean birth weight 2.14 ± 0.59 vs 2.00 ± 0.44 kg in group A and B respectively. Though low birth weight rate was a bit higher in group B, which is not significant. So NICU referral was also higher in group B 71.4% and 50% in group A (Table V) . shows significance difference. Two patients died from group A, though it might not be related to dose schedule as number of convulsion was not very different and there was no recurrent convulsion. Both of them were poor prognostic with pulmonary oedema. Though complication rate shows significant difference, death rate did not show the same.
Discussion:
Eclampsia is a multisystem disorder with complex pathogenesis, which is not completely understood.
Control of convulsion and prevention of recurrence is one of the most important parts of management of eclampsia. There is now conclusive evidence that the best available anticonvulsant for women who have had an eclamptic fit is magnesium sulphate 6-8. Bangladesh is a developing country where the incidence of eclampsia is very high, and eclampsia remains the leading cause of death in large tertiary level hospitals such as Dhaka Medical College Hospital (DMCH) for many years. MgSO 4 is being used as a routine anticonvulsant in different obstetric centers of Bangladesh since 1998, but the dose that is recommended by Bangladesh Eclampsia Working Group is much lower than that used in the Eclampsia Collaborative Trial (10gm loading dose compared to 14gm loading dose). The lower dose is chosen considering the smaller size of Bangladeshi women and concerns about toxicity in circumstances in which measuring serum magnesium levels would be difficult. Its efficacy in controlling convulsions and preventing recurrences has been established in many prospective studies. Studies showed that half of the standard dose of MgSO 4 appeared to be sufficient to control convulsion effectively and serum level of MgSO 4 remained lower than levels which produced toxicity 2, 5 . A randomized controlled trial compared the effect of only loading dose and standard regimen for controlling of convulsion and showed the similarity of both the regimes in terms of controlling convulsion and recurrent convulsion rate. Recurrent convulsion rate was almost the same in both groups (3.96% in loading vs 3.51% in standard regime). Conclusion of the study was that only loading dose of MgSO 4 can control convulsion in eclampsia and it is as effective as standard regime. 5 Cosidering the result of this study 8 gm loading dose is not under dose where maintenance dose is continued So this study was conducted with a view to use 8 gm of Magnesium Heptahydrate (only IV ) as a loading dose in the management of convulsion in eclamptic patients, and the observations were compared with those of 10 gm of MgSO 4 ( both IV and IM ). This has the advantages of being more simplified administration and need of less efficiency of healthcare providers. Moreover, painful IM injection can be avoided and it is more economic and can reduce the risk of toxicity.
None of the parameters were statistically significant. The mean time interval between 1st convulsion and treatment was 7.10 ± 2.91 versus 7.08 ± 2.22 hours. The mean time interval between 1st convulsion and delivery was 13.34 ± 5.38 versus 13.36 ± 5.39 hours.
Only 10 percent patients of group A and 15 percent of group B experienced recurrent convulsion.
Mode of delivery, mean birth weight of the baby, birth asphyxia were similar in both groups. Low birth weight rate was higher in group B and NICU referral was also higher in that group though it has got no relationship with dose schedule. Table VI showed time required to regain consciousness. There was no statistically significant difference in regaining consciousness which was 36.93 ± 19.01 versus and 34.69 ± 14.66 hours in group A and Group B respectively. Table VII shows the maternal outcome. There was statistically significant difference in term of maternal complications in group A and group B. P value was 0.044. The most commonest complication was pulmonary oedema. Two patients of pulmonary oedema from group A died and the death was not related to dose schedule as number of convulsion was comparable with group B and there was no recurrent convulsion. Even then there was significant difference in death rate between groups.
In conclusion it can be said that existing loading dose can be changed to 8 gm IV from 10gm IV and IM as there is no difference in treatment outcome. Rather it can avoid voluminous (6ml) painful intramuscular injection. However, a large scale study needs to be conducted to reach to a definitive conclusion.
